Initial Statement of Beneficial Ownership (3)
March 09 2022 - 4:54PM
Edgar (US Regulatory)
FORM 3
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0104
Estimated average burden hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
Warren Eric |
2. Date of Event Requiring Statement (MM/DD/YYYY)
3/1/2022
|
3. Issuer Name and Ticker or Trading Symbol
Esperion Therapeutics, Inc. [ESPR]
|
(Last)
(First)
(Middle)
C/O ESPERION THERAPEUTICS, INC., 3891 RANCHERO DRIVE, SUITE 150 |
4. Relationship of Reporting Person(s) to Issuer (Check all applicable)
_____ Director _____ 10% Owner ___X___ Officer (give title below) _____ Other (specify below) Chief Commercial Officer / |
(Street)
ANN ARBOR, MI 48108
(City)
(State)
(Zip)
| 5. If Amendment, Date Original Filed(MM/DD/YYYY)
| 6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Beneficially Owned
|
1.Title of Security (Instr. 4) | 2. Amount of Securities Beneficially Owned (Instr. 4) | 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 4. Nature of Indirect Beneficial Ownership (Instr. 5) |
Common Stock | 11207 (1) | D | |
Common Stock | 5899 (2) | D | |
Common Stock | 24000 (3) | D | |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security (Instr. 4) | 2. Date Exercisable and Expiration Date (MM/DD/YYYY) | 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) | 4. Conversion or Exercise Price of Derivative Security | 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5) | 6. Nature of Indirect Beneficial Ownership (Instr. 5) |
Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
Explanation of Responses: |
(1) | These shares were acquired pursuant to a restricted stock unit award under the 2017 Inducement Equity Plan. Each restricted stock unit represents a contingent right to receive one share of Esperion Therapeutics, Inc. common stock. The restricted stock unit vests over a four-year period with 25% of the shares underlying the option vesting on the one-year anniversary of February 15, 2021, and 1/16th vesting on each quarterly anniversary of such date thereafter, subject to continued employment through each such date. |
(2) | These shares were acquired pursuant to a restricted stock unit award under the Amended and Restated 2013 Stock Option and Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of Esperion Therapeutics, Inc. common stock. The restricted stock unit vests over a four-year period with 25% of the shares underlying the option vesting on the one-year anniversary of July 15, 2021, and 1/16th vesting on each quarterly anniversary of such date thereafter, subject to continued employment through each such date. |
(3) | These shares were acquired pursuant to a performance-based restricted stock unit award under the Amended and Restated 2013 Stock Option and Incentive Plan. Each performance-based restricted stock unit represents a contingent right to receive one share of Esperion Therapeutics, Inc. common stock. The awards will vest as follows: 50% shall vest upon CVOT public presentation of results; and 50% shall vest upon obtaining approval for cardiovascular risk reduction into the U.S. label. |
Reporting Owners
|
Reporting Owner Name / Address | Relationships |
Director | 10% Owner | Officer | Other |
Warren Eric C/O ESPERION THERAPEUTICS, INC. 3891 RANCHERO DRIVE, SUITE 150 ANN ARBOR, MI 48108 |
|
| Chief Commercial Officer |
|
Signatures
|
/s/ Richard B. Bartram, by power of attorney | | 3/9/2022 |
**Signature of Reporting Person | Date |
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. |
* | If the form is filed by more than one reporting person, see Instruction 5(b)(v). |
** | Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). |
Note: | File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. |
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. |
Esperion Therapeutics (NASDAQ:ESPR)
Historical Stock Chart
From Jun 2024 to Jul 2024
Esperion Therapeutics (NASDAQ:ESPR)
Historical Stock Chart
From Jul 2023 to Jul 2024